Sumiti Jain

Title: The Innovative Contributions of Sumiti Jain

Introduction

Sumiti Jain is a prominent inventor based in Richmond, CA (US). She has made significant contributions to the field of biotechnology, particularly in the area of T cell and HLA receptor disruption. Her innovative work has the potential to advance therapeutic strategies in immunology.

Latest Patents

Sumiti Jain holds a patent for "Targeted disruption of T cell and/or HLA receptors." This patent discloses methods and compositions for inactivating TCR and/or HLA genes. The invention utilizes engineered nucleases that comprise at least one DNA binding domain and a cleavage domain or cleavage half-domain, all while preserving cell viability. Additionally, the patent includes polynucleotides encoding nucleases, vectors comprising these polynucleotides, and cells that incorporate them.

Career Highlights

Sumiti Jain is currently employed at Sangamo Therapeutics, Inc., where she continues to push the boundaries of genetic engineering and therapeutic development. Her work is instrumental in exploring new avenues for treating various diseases through targeted gene editing.

Collaborations

Some of her notable coworkers include Anthony Conway and Gary K Lee, who collaborate with her on various projects within the company.

Conclusion

Sumiti Jain's contributions to biotechnology and her innovative patent work exemplify the impact of dedicated inventors in advancing medical science. Her efforts in targeted gene disruption are paving the way for future breakthroughs in immunotherapy.